Article
Medicine, General & Internal
Sandeep Dhindsa, Cosette Champion, Ekamjit Deol, Matthew Lui, Robert Campbell, Jennifer Newman, Aparna Yeggalam, Srikanth Nadella, Vaishaliben Ahir, Ekta Shrestha, Thomas Kannampallil, Abhinav Diwan
Summary: This study suggests that men with hypogonadism are more likely to be hospitalized after COVID-19 infection compared to those with eugonadism, while men receiving adequate TTh do not have this increased risk.
Review
Medicine, Research & Experimental
Marcelo Rodrigues dos Santos, Shalender Bhasin
Summary: The increase in life expectancy for men has drawn attention to quality-of-life issues related to reproductive aging. Testosterone levels decline with age and can be improved with treatment, although long-term effects on major cardiovascular events and prostate cancer risk remain unclear.
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021
(2021)
Article
Endocrinology & Metabolism
Giovanni Corona, Mario Maggi
Summary: Sexual function and testosterone levels decline in aging men, but the specific contribution of low testosterone to sexual impairment is still uncertain. Testosterone replacement therapy is effective but has variable effects. Lifestyle interventions can also yield similar outcomes. Therefore, phosphodiesterase type 5 inhibitors and lifestyle measures should be considered as the first line of treatment for erectile dysfunction, with testosterone replacement therapy reserved for cases where other interventions fail.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
(2022)
Article
Endocrinology & Metabolism
Peter Snyder
Summary: As men age, their serum testosterone concentration declines, especially in the free testosterone concentration. Testosterone treatment can improve several consequences of this decline in older men with low testosterone concentrations, but it may also increase some risks.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
(2022)
Review
Pharmacology & Pharmacy
Giovanni Corona, Clotilde Sparano, Giulia Rastrelli, Linda Vignozzi, Mario Maggi
Summary: The specific role of testosterone replacement therapy in late onset hypogonadism is still debated. Different preparations have been developed for different purposes, and their advantages and limitations are discussed. The selection of a specific testosterone preparation should be discussed with each patient. Transdermal preparations can maintain the circadian rhythmicity of testosterone secretion, while short-acting preparations may require more frequent administration. Long-acting preparations, such as injectable testosterone undecanoate, offer the advantage of less frequent administration. The use of non-steroidal selective androgen receptor modulators (SARMs) is still investigational, despite their potential use in the treatment of muscle wasting and osteoporosis.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Review
Endocrinology & Metabolism
Bac Nguyen Hoai, Long Hoang, Thang Nguyen Cao, Quan Pham Minh, Emmanuele A. JanninI
Summary: Hypogonadism can have a significant impact on men's physical and psychological health, but diagnosing and treating it in developing countries can be challenging due to lack of awareness, limited resources, and high treatment costs. This review examines the potential benefits and risks of testosterone replacement therapy (TRT) from the perspective of a developing country.
Article
Endocrinology & Metabolism
Mathis Grossmann, Channa N. Jayasena, Bradley D. Anawalt
Summary: Although testosterone replacement therapy is commonly used for men with classical hypogonadism, its role in age-related decline of testosterone remains unclear due to limited evidence from long-term clinical trials. However, men aged 50 years and above with comorbidities and higher body mass index often exhibit symptoms of androgen deficiency and low testosterone levels. Clinicians face a challenging dilemma in initiating testosterone therapy and must carefully assess the benefits and risks based on limited clinical trial data. In this article, a practical approach to the assessment and management of such men is presented using a case scenario.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Andrology
Anthony DelConte, Kongnara Papangkorn, Kilyoung Kim, Benjamin J. Bruno, Nachiappan Chidambaram, Mohit Khera, Irwin Goldstein, Tobias S. Kohler, Martin Miner, Adrian S. Dobs, Mahesh Patel
Summary: This study evaluated the efficacy and safety of a novel oral testosterone undecanoate therapy for hypogonadism. The results showed that this therapy could restore testosterone levels to the normal range in the majority of patients and was well tolerated.
Review
Endocrinology & Metabolism
Rita Indirli, Valeria Lanzi, Maura Arosio, Giovanna Mantovani, Emanuele Ferrante
Summary: According to WHO, 5% of adults worldwide suffer from depression. Men with depression often report sexual dysfunction. Decreased libido, erectile dysfunction, and orgasmic disorder are common manifestations. Depression may cause male functional hypogonadism. Antidepressants can worsen sexual complaints. The interaction between depression and male hypogonadism and the effect of treatment on both conditions are still unclear.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Editorial Material
Medicine, General & Internal
Howard Libman, Marc L. Cohen, Michael S. Irwig, Gerald W. Smetana
Summary: Male hypogonadism is characterized by abnormally low serum testosterone concentration or sperm count. As men age, their serum testosterone levels may decrease, and normalizing these levels could improve symptoms related to androgen deficiency.
ANNALS OF INTERNAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Daniel B. Martinez-Arguelles, Jennifer W. Nedow, Hovhannes J. Gukasyan, Vassilios Papadopoulos
Summary: Cholesterol is the rate-limiting step of steroidogenesis, and its entry into mitochondria is controlled by Voltage-dependent anion channel (VDAC1). This study presents the development of a new class of small molecules that increase testosterone levels specifically by targeting VDAC1. The study involves the identification of a biologically active core peptide and the design of synthetic derivatives that can be administered orally. Several active compounds were identified, and dose-response experiments narrowed down to 4 synthetic peptides that significantly increased androgen levels.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Biagio Barone, Luigi Napolitano, Marco Abate, Luigi Cirillo, Pasquale Reccia, Francesco Passaro, Carmine Turco, Simone Morra, Francesco Mastrangelo, Antonio Scarpato, Ugo Amicuzi, Vincenzo Morgera, Lorenzo Romano, Francesco Paolo Calace, Savio Domenico Pandolfo, Luigi De Luca, Achille Aveta, Enrico Sicignano, Massimiliano Trivellato, Gianluca Spena, Carlo D'Alterio, Giovanni Maria Fusco, Raffaele Vitale, Davide Arcaniolo, Felice Crocetto
Summary: Testosterone is the most important hormone in male health, and aging can result in testosterone deficiency. Testosterone replacement therapy can restore testosterone levels in men, improving sexual dysfunction, increasing bone density and muscle strength, and providing cardioprotective effects. However, it may be contraindicated in men with untreated prostate cancer and may have other potential side effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Lello Zolla, Marcello Ceci
Summary: In male hypogonadism patients, testosterone replacement therapy (TRT) improves glucose utilization, branched amino acid and carnosine metabolism, but does not activate fatty acid oxidation. Lipid metabolism shows delayed improvement, and both malate and glycerol shuttle are reduced, leading to lower NADH and ATP levels, with increased lactate production.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Endocrinology & Metabolism
Maria Gabriela Figueiredo, Thiago Gagliano-Juca, Shehzad Basaria
Summary: This article reviews the pharmacokinetics and safety of subcutaneous testosterone therapy and provides guidance for clinicians on counseling and managing patients who choose this route. Limited evidence suggests that subcutaneous administration results in comparable pharmacokinetics and testosterone levels as intramuscular injection. The subcutaneous route is easier for self-administration and has the potential to improve patient adherence.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Andrology
Andrew Morton, Michael Williams, Marlon Perera, Sachinka Ranasinghe, Patrick E. Teloken, Marissa Williams, Eric Chung, Matthew J. Roberts
Summary: Testosterone replacement therapy (TRT) subsidized by the Pharmaceutical Benefits Scheme (PBS) in Australia has shown a progressive increase in overall prescriptions since 2000, with a decline observed after stricter prescription criteria were implemented in 2015. The majority of contemporary TRT now consists of injections and 1% gel, with a slowdown in the rate of financial burden increase after the restrictions were introduced.
WORLD JOURNAL OF MENS HEALTH
(2021)
